Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model

Journal of Investigative Dermatology

Volumn 135, Issue 7, 2015, Pages 1912-1915

  Chan, Emilie S ^a   Herlitz, Leal C ^b   Jabbari, Ali ^b  

^a Columbia University ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB; AUTOANTIBODY; COMPLEMENT COMPONENT C3; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; INTERFERON RECEPTOR; INTERFERON RECEPTOR TYPE 1; INTERFERON RECEPTOR TYPE 2; INTERLEUKIN 17; PROTEIN KINASE TYK2; UNCLASSIFIED DRUG; JANUS KINASE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; FEMALE; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; LETTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIBODY PRODUCTION; CD3+ T LYMPHOCYTE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVATION; EPIDERMIS HYPERPLASIA; HUMAN; INFLAMMATORY INFILTRATE; KIDNEY DISEASE; LYMPHADENOPATHY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; SIGNAL TRANSDUCTION; SPLEEN CELL; SPLENOMEGALY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, CUTANEOUS; NEEDLE BIOPSY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; BIOPSY, NEEDLE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; JANUS KINASES; LUPUS ERYTHEMATOSUS, CUTANEOUS; MICE; MICE, INBRED MRL LPR; PYRAZOLES; RANDOM ALLOCATION; TREATMENT OUTCOME;

EID: 84931078951     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.107     Document Type: Letter

References (20)

1. Braun D, Demengeot J (2003) Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20:15-25
2. Crispín JC, Oukka M, Bayliss G, et al. (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181: 8761-6
3. Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192:5459-68
4. Fridman JS, Scherle PA, Collins R, et al. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 131:1838-44
5. Furukawa F (1997) Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Lupus 6:193-202
6. Furukawa F, Tanaka H, Sekita K, et al. (1984) Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 276:186-94
7. Ghoreishi M, Dutz JP (2010) Cutaneous lupus erythematosus: recent lessons from animal models. Lupus 19:1029-35
8. Harrison C, Kiladjian J-J, Al-Ali HK, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-98
9. Hron JD, Peng SL (2004) Type I IFN protects against murine lupus. J Immunol 173:2134-42
10. Jabbari A, Suárez-Fariñas M, Fuentes-Duculan J, et al. (2014) Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol 134:87-95
11. Jacob CO, van der Meide PH, McDevitt HO (1987) In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 166: 798-803
12. Jessop S, Whitelaw D, Jordaan F (2000) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev (4):CD002954
13. Kanauchi H, Furukawa F, Imamura S (1991) Characterization of cutaneous infiltrates in MRL/1pr mice monitored from onset to the full development of lupus erythematosuslike skin lesions. J Invest Dermatol 96: 478-83
14. Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227-55
15. Peng SL, Mosiehi J, Craft J (1997) Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 99:1936-46
16. Platanias LC (2005) Mechanisms of type-I-And type-II-interferon-mediated signalling. Nat Rev Immunol 5:375-86
17. Punwani N, Scherle P, Flores R, et al. (2012) Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 67:658-64
18. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197:777-88
19. Verstovsek S, Mesa RA, Gotlib J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.NEngl J Med 366:799-807
20. Zhang Z, Kyttaris VC, Tsokos GC (2009) The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 183:3160-9